探索用于多发性硬化症药理疗的单克隆抗体诱导的自身免疫内分泌疾病:系统性审查
Mohammad Ali Sahraian1, Shahaboddin Emami2, Sara Ataei2
1Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Naunyn-Schmiedeberg's archives of pharmacology
|September 9, 2024
概括
用于多发性硬化症 (MS) 的单克隆抗体 (MAb) 很少会导致二次自身免疫性疾病,如甲状腺炎. 在治疗多发性硬化症的MAb治疗期间,建议对患者进行仔细监测.
科学领域:
- 神经免疫学 神经免疫学
- 这是一种自身免疫力.
- 药物监督 药物监督 药物监督
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性神经退行性疾病,向髓.
- 单克隆抗体 (MAb) 是MS的常见免疫疗法,可以控制疾病的进展和恶化.
- 与MAb治疗相关的一种罕见不良事件是诱导二级自身免疫性疾病.
研究的目的:
- 系统地审查和综合从病例报告中获得的关于二次性自身免疫性疾病的数据,这些疾病是由多发性硬化症患者中MAb引起的.
- 阐明潜在的机制,这些二级自身免疫条件的发展背后的潜在机制.
主要方法:
- 在PubMed,Scopus和Google Scholar进行了系统的文献搜索,查找2024年2月21日之前发表的案例报告.
- 乔安娜·布里格斯研究所 (JBI) 批判性评估检查清单被用来评估所包含的研究的质量.
- 20篇文章符合纳入标准,并被纳入审查.
主要成果:
- 该审查确定了二级自身免疫性疾病,最常见的甲状腺炎,作为MSMAb治疗的罕见并发症.
- 阿莱姆图祖马布经常与诱导的自身免疫性疾病有关.
- 奥克雷利祖马布与一种报告的二次自身免疫并发症有关.
结论:
- 在多发性硬化症免疫治疗中使用的单克隆抗体可以导致二次自身免疫性疾病,包括内分泌并发症.
- 这些发现强调了在MS治疗中谨慎使用MAb药物的重要性.
- 在MAb治疗期间,持续监测患者的症状表明二级自身免疫性疾病至关重要.
相关概念视频
01:29Autoimmune Disorders
396
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
396
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118